SCHEMBL4598326

SCHEMBL4598326

NS(=O)(=O)c1cccc(CNc2c(Nc3ccc(O)c(-c4ccccn4)c3)c(=O)c2=O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 1/20 0.41
ROCK2 O75116 4/20 0.40
GSK3B P49841 4/20 0.40
ROCK1 Q13464 4/20 0.40
PKN2 Q16513 4/20 0.40
AURKB Q96GD4 4/20 0.40
CLK2 P49760 3/20 0.40
PRKG2 Q13237 3/20 0.40
CLK4 Q9HAZ1 3/20 0.40
CHEK2 O96017 3/20 0.40
PRKACA P17612 3/20 0.40
RPS6KB1 P23443 3/20 0.40
AKT1 P31749 3/20 0.40
RPS6KA3 P51812 3/20 0.40
PRKG1 Q13976 3/20 0.40
CDC42BPA Q5VT25 3/20 0.40
HIPK4 Q8NE63 3/20 0.40
CHEK1 O14757 2/20 0.40
DAPK3 O43293 2/20 0.40
AKT2 P31751 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4598469 0.90 ROCK1 (0.41) MAPKAPK2ROCK2GSK3BROCK1PKN2
SCHEMBL4598269 0.88 KDM1A (0.46) MAPKAPK2ROCK2GSK3BROCK1PKN2
SCHEMBL4924199 0.88 KDM1A (0.47) MAPKAPK2ROCK2GSK3BROCK1PKN2
SCHEMBL4920334 0.86 MAPKAPK2 (0.42) MAPKAPK2ROCK2GSK3BROCK1PKN2
SCHEMBL13991825 0.86 MAPKAPK2 (0.42) MAPKAPK2ROCK2GSK3BROCK1PKN2
SCHEMBL4919461 0.85 GPR39 (0.42) MAPKAPK2ROCK2GSK3BROCK1PKN2
SCHEMBL4930829 0.85 MAPKAPK2 (0.44) MAPKAPK2ROCK2GSK3BROCK1PKN2
SCHEMBL4930944 0.83 MAPKAPK2 (0.44) MAPKAPK2ROCK2GSK3BROCK1PKN2
SCHEMBL4928235 0.83 KDM4C (0.49) MAPKAPK2ROCK2GSK3BROCK1PKN2
SCHEMBL4928614 0.83 AURKB (0.57) MAPKAPK2ROCK2GSK3BROCK1PKN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312244-A1 Squaric Acid Derivatives as Protein Kinase Inhibitors MERCK PATENT GMBH (DE) 2008-12-18 US claimed
EP-1910277-A1 QUADRATIC ACID DERIVATIVES IN THE FORM OF A PROTEIN KINASE INHIBITORS Merck Patent GmbH (DE) 2008-04-16 EP claimed
WO-2007014607-A1 QUADRATIC ACID DERIVATIVES IN THE FORM OF A PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2007-02-08 WO claimed
US-20080312244-A1 Squaric Acid Derivatives as Protein Kinase Inhibitors MERCK PATENT GMBH (DE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312244-A1 Squaric Acid Derivatives as Protein Kinase Inhibitors CHEK1, CHEK2, SIK1 MAPKAPK2 377/4885ROCK2 825/4885GSK3B 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.